Significantly Greater Tolerance to Inhibitors Found in Whole Blood and Anticoagulants (K2-Edta, Sodium Heparin, and Sodium Citrate)
A) Lyo-Ready Direct DNA qPCR Blood (MDX122)
B) Lyo-Ready Direct RNA/DNA qPCR Blood (MDX123)
45
45
40
40
35
35
30
30
25
25
10%
2%
5%
10
2%
5%
2%
5%
10%
0%
2%
5%
0%
2%
5%
0%
2%
5% 10%
%
10%
10%
®
TaqPath™
TaqPath™
MDX122
KAPA Probe Force (Roche)
MDX123
UltraPlex (Quantabio)
(ThermoFisher)
(ThermoFisher)
EDTA | Heparin| Citrate
Anticoagulants and high concentrations of whole blood are known to inhibit qPCR efficiencies. In this experiment, 0%, 2%, 5% and 10% whole human blood in the presence of K2-EDTA ( orange ), sodium heparin ( green ) or sodium citrate ( grey ) was tested with (A) Lyo-Ready Direct DNA qPCR Blood (MDX122) against KAPA Probe Force (Roche) and TaqPath™ (Thermo) and (B) Lyo-Ready Direct RNA/DNA qPCR Blood (MDX123) against UltraPlex™ 1-Step ToughMix® (QuantaBio) and TaqPath™ 1-Step Multiplex Master Mix (Thermo). The results demonstrate that the reaction efficiencies of the Lyo-Ready Direct Blood mixes are higher in the presence of inhibitors found in anticoagulants and high concentrations of blood.
High Multiplexing Capacity EnablesThe Detection Of Multiple Analytes From Crude, Inhibitor-Rich Plasma, Serum And Whole Blood Samples
Lyo-Ready Direct DNA qPCR Blood (MDX122)
S. aureus
P. falciparum
Epstein-Bar virus
Lyo-Ready Direct DNA qPCR Blood | KAPA Probe Force | TaqPath TM ProAMP TM Mix
Three diagnostic DNA targets ( Staphylococcus aureus , Plasmodium falciparum and Epstein-Bar virus) were amplified in a triplex reaction using lyophilized Lyo-Ready Direct DNA qPCR Blood (MDX122, red ), KAPA Probe Force ( green ) or TaqPath™ ProAmp TM Mix ( black ) in the presence of 10% EDTA plasma or 10% serum. The results illustrate that Lyo-Ready Direct DNA qPCR Blood has higher multiplexing capacity and performance than KAPA Probe Force and TaqPath™ ProAmp™ Mix.
www.meridianbioscience.com/lifescience
Powered by FlippingBook